Literature DB >> 19158820

Characterization of deletion breakpoints in patients with dystrophinopathy carrying a deletion of exons 45-55 of the Duchenne muscular dystrophy (DMD) gene.

Daigo Miyazaki1, Kunihiro Yoshida, Kazuhiro Fukushima, Akinori Nakamura, Kayo Suzuki, Toshiyuki Sato, Shin'ichi Takeda, Shu-ichi Ikeda.   

Abstract

Deletion of exons 45-55 (del45-55) in the Duchenne muscular dystrophy gene (DMD) has gained particular interest in the field of molecular therapy, because it causes a milder phenotype than DMD, and therefore, may represent a good candidate for the goal of a multiple exon-skipping strategy. We have precisely characterized deletion breakpoints in three patients with del45-55 in DMD. Two of them were young adult males of the X-linked dilated cardiomyopathy phenotype, and the third patient revealed the mild Becker muscular dystrophy phenotype of late onset. The deletion breakpoints differed among patients. The deletion started at nt 226 604, 231 518, 117 284 in intron 44, and ended at nt 64 994, 59 314, 71 806 in intron 55, respectively. Deletion junctions showed no significant homology between the sequences adjacent to the distal and proximal end joints in these patients. Deletion breakpoints were not primarily associated with any particular sequence element, or with a matrix attachment region. However, there were several palindromic sequences and short tandem repeats at or near the breakpoints. These sequences, with a marked propensity to form secondary DNA structure intermediates, may predispose local DNA to breakage and intragenic recombination in these patients.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19158820     DOI: 10.1038/jhg.2008.8

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  7 in total

1.  Cardiac-Specific Expression of ΔH2-R15 Mini-Dystrophin Normalized All Electrocardiogram Abnormalities and the End-Diastolic Volume in a 23-Month-Old Mouse Model of Duchenne Dilated Cardiomyopathy.

Authors:  Nalinda B Wasala; Jin-Hong Shin; Yi Lai; Yongping Yue; Federica Montanaro; Dongsheng Duan
Journal:  Hum Gene Ther       Date:  2018-03-22       Impact factor: 5.695

2.  Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials.

Authors:  Karen Anthony; Sebahattin Cirak; Silvia Torelli; Giorgio Tasca; Lucy Feng; Virginia Arechavala-Gomeza; Annarita Armaroli; Michela Guglieri; Chiara S Straathof; Jan J Verschuuren; Annemieke Aartsma-Rus; Paula Helderman-van den Enden; Katherine Bushby; Volker Straub; Caroline Sewry; Alessandra Ferlini; Enzo Ricci; Jennifer E Morgan; Francesco Muntoni
Journal:  Brain       Date:  2011-11-18       Impact factor: 13.501

3.  Precise mapping of 17 deletion breakpoints within the central hotspot deletion region (introns 50 and 51) of the DMD gene.

Authors:  Gabriella Esposito; Maria Roberta Tremolaterra; Evelina Marsocci; Igor Cm Tandurella; Tiziana Fioretti; Maria Savarese; Antonella Carsana
Journal:  J Hum Genet       Date:  2017-09-07       Impact factor: 3.172

Review 4.  Skipping Multiple Exons to Treat DMD-Promises and Challenges.

Authors:  Tejal Aslesh; Rika Maruyama; Toshifumi Yokota
Journal:  Biomedicines       Date:  2018-01-02

5.  Clinical features of patients with dystrophinopathy sharing the 45-55 exon deletion of DMD gene.

Authors:  Antonella Taglia; Roberta Petillo; Paola D'Ambrosio; Esther Picillo; Annalaura Torella; Chiara Orsini; Manuela Ergoli; Marianna Scutifero; Luigia Passamano; Alberto Palladino; Gerardo Nigro; Luisa Politano
Journal:  Acta Myol       Date:  2015-05

6.  Fast detection of deletion breakpoints using quantitative PCR.

Authors:  Gulshara Abildinova; Zhanara Abdrakhmanova; Helena Tuchinsky; Elimelech Nesher; Albert Pinhasov; Leon Raskin
Journal:  Genet Mol Biol       Date:  2016-06-16       Impact factor: 1.771

Review 7.  Development of multiexon skipping antisense oligonucleotide therapy for Duchenne muscular dystrophy.

Authors:  Yoshitsugu Aoki; Toshifumi Yokota; Matthew J A Wood
Journal:  Biomed Res Int       Date:  2013-07-31       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.